Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Fiona Stewart, Kristin Kistler, Yuxian Du, Rakesh R. Singh, Bonnie B. Dean & Sheldon X. Kong. (2024) Exploring kidney dialysis costs in the United States: a scoping review. Journal of Medical Economics 27:1, pages 618-625.
Read now
Read now
Abiy Agiro, Jamie P Dwyer, Yemisi Oluwatosin & Pooja Desai. (2023) Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study. ClinicoEconomics and Outcomes Research 15, pages 691-702.
Read now
Read now
Charles V. Pollack$suffix/text()$suffix/text(), Abiy Agiro, Fan Mu, Erin E. Cook, Esteban Lemus Wirtz, Joshua A. Young, Keith A. Betts & Yasmin G. Brahmbhatt. (2023) Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study. Expert Review of Pharmacoeconomics & Outcomes Research 23:2, pages 241-250.
Read now
Read now
Jill Davis, Rubeen Israni, Fan Mu, Erin E. Cook, Harold Szerlip, Gabriel Uwaifo, Vivian Fonseca & Keith A. Betts. (2021) Inpatient management and post-discharge outcomes of hyperkalemia. Hospital Practice 49:4, pages 273-279.
Read now
Read now
Nihar R. Desai, Paula J. Alvarez, Ladan Golestaneh, Steven D. Woods, Steven G. Coca & Christopher G. Rowan. (2021) Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients. Journal of Medical Economics 24:1, pages 1025-1036.
Read now
Read now
Articles from other publishers (22)
Preh Arbab, Zofishan Anwar, Raveeha Aamir & Fareed Ahmed. (2024) Acquired hyperkalaemia leading to periodic paralysis: an emergency department perspective. BMJ Case Reports 17:5, pages e260151.
Crossref
Crossref
Christopher G. Rowan, Abiy Agiro, K. Arnold Chan, Ellen Colman, Katie White, Pooja Desai & Jamie P. Dwyer. (2024) Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3–4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Advances in Therapy.
Crossref
Crossref
Diederick E. Grobbee, Gerasimos Filippatos, Nihar R. Desai, Andrew J. S. Coats, Fausto Pinto, Giuseppe M. C. Rosano, John G. F. Cleland, Jennifer Kammerer & Antonio Ramirez de Arellano. (2024) Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Failure.
Crossref
Crossref
William B. EarleGeorge OrmsethMartha Catalina Morales-AlvarezMilan Kaushik & Stephen P. Juraschek. (2024) Dietary Sodium Reduction Is Best for Reducing Blood Pressure: Controversies in Hypertension. Hypertension 81:3, pages 510-515.
Crossref
Crossref
Byung Sik Kim, Mi-Yeon Yu & Jinho Shin. (2024) Effect of low sodium and high potassium diet on lowering blood pressure and cardiovascular events. Clinical Hypertension 30:1.
Crossref
Crossref
Randah Dahlan & Ali Alkatheeri. 2024. Exploring the Causes and Treatments of Chronic Kidney Disease [Working Title]. Exploring the Causes and Treatments of Chronic Kidney Disease [Working Title].
Aneesh GuptaJennifer KammererImran ShaikKathakali G. MukherjeeJuliana OliveiraCharuhas Thakar. (2024) Evaluation of longer- vs short-term use of patiromer on health care resource utilization in the patiromer longer-term use evaluation (VALUE) study. Journal of Managed Care & Specialty Pharmacy 30:1, pages 52-60.
Crossref
Crossref
Jamie P. Dwyer, Abiy Agiro, Pooja Desai & Yemisi Oluwatosin. (2023) Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study. Advances in Therapy 40:11, pages 4777-4791.
Crossref
Crossref
Hugh Logan Ellis, David Llewellyn, Jeewaka Mendis & Martin Whyte. (2023) Admission plasma potassium and length of hospital stay: a meta-analysis. BMJ Open 13:8, pages e068387.
Crossref
Crossref
Voravech Nissaisorakarn, George Ormseth, William Earle, Martha Catalina Morales-Alvarez, Swapnil Hiremath & Stephen P. Juraschek. (2023) Less sodium, more potassium, or both: population-wide strategies to prevent hypertension. American Journal of Physiology-Renal Physiology 325:1, pages F99-F104.
Crossref
Crossref
James O Burton, Alaster M Allum, Alpesh Amin, Cecilia Linde, Eva Lesén, Carl Mellström, James M Eudicone & Manish M Sood. (2023) Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease. Clinical Kidney Journal 16:7, pages 1160-1169.
Crossref
Crossref
Hsin-Hsiung Chang, Jung-Hsien Chiang, Chun-Chieh Tsai & Ping-Fang Chiu. (2023) Predicting hyperkalemia in patients with advanced chronic kidney disease using the XGBoost model. BMC Nephrology 24:1.
Crossref
Crossref
Eiichiro Kanda, Naru Morita & Toshitaka Yajima. (2023) Impact of chronic potassium binder treatment on the clinical outcomes in patients with hyperkalemia: Results of a nationwide hospital-based cohort study. Frontiers in Physiology 14.
Crossref
Crossref
Natasha L. Larivée, Jacob B. Michaud, Keigan M. More, Jo-Anne Wilson & Karthik K. Tennankore. (2022) Hyperkalemia: Prevalence, Predictors and Emerging Treatments. Cardiology and Therapy 12:1, pages 35-63.
Crossref
Crossref
James F. Neuenschwander, Alison R. Silverstein, Christie L. Teigland, Shambhavi Kumar, Edric Y. Zeng, Abiy T. Agiro, William J. Pottorf & W. Frank Peacock. (2023) The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings. Advances in Therapy 40:3, pages 1204-1223.
Crossref
Crossref
John S. Babich, Kamyar Kalantar-Zadeh & Shivam Joshi. (2022) Taking the Kale out of Hyperkalemia: Plant Foods and Serum Potassium in Patients With Kidney Disease. Journal of Renal Nutrition 32:6, pages 641-649.
Crossref
Crossref
Pietro Scicchitano, Massimo Iacoviello, Francesco Massari, Micaela De Palo, Pasquale Caldarola, Antonia Mannarini, Andrea Passantino, Marco Matteo Ciccone & Michele Magnesa. (2022) Optimizing Therapies in Heart Failure: The Role of Potassium Binders. Biomedicines 10:7, pages 1721.
Crossref
Crossref
Abiy Agiro, Ian Duling, James Eudicone, Jill Davis, Yasmin G. Brahmbhatt & Kerry Cooper. (2022)
The prevalence of predialysis hyperkalemia and associated characteristics among hemodialysis patients: The
RE‐UTILIZE
study
. Hemodialysis International 26:3, pages 397-407.
Crossref
Crossref
Carol Pollock, Glen James, Juan Jose Garcia Sanchez, Matthew Arnold, Juan-Jesus Carrero, Carolyn S. P. Lam, Hungta Chen, Stephen Nolan & Roberto Pecoits-Filho. (2022) Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort. Advances in Therapy 39:3, pages 1432-1445.
Crossref
Crossref
Arnav A. Gupta, Michael Self, Matthew Mueller, Gabriel Wardi & Christopher Tainter. (2022) Dispelling myths and misconceptions about the treatment of acute hyperkalemia. The American Journal of Emergency Medicine 52, pages 85-91.
Crossref
Crossref
Erin E. Cook, Jill Davis, Rubeen Israni, Fan Mu, Keith A. Betts, Deborah Anzalone, Lei Yin, Harold Szerlip, Gabriel I. Uwaifo, Vivian Fonseca & Eric Q. Wu. (2021) Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia. Advances in Therapy 38:10, pages 5238-5252.
Crossref
Crossref
Umar Ismail, Kiran Sidhu & Shelley Zieroth. (2021) Hyperkalaemia in Heart Failure. Cardiac Failure Review 7.
Crossref
Crossref